EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

QbD BASED DEVELOPMENT, OPTIMIZATION AND EVALUATION OF CYCLODEXTRIN INCLUSION COMPLEX LOADED MATRIX TABLET FORMULATION OF FAMOTIDINE

Shabnam Ain*, Babita Kumar and Kamla Pathak

ABSTRACT

Famotidine is a potent histamine receptor (H2) blocker employed in the treatment of zollinger ellision syndrome, gastro esophageal reflux disease and peptic ulcer. It is poorly absorbed from the GI tract upon oral administration. The poor bioavailability (40-45%) with shorter biological half-life (2.5-4 hrs) of famotidine upon oral administration encourages the development of a controlled release formulation. The cyclodextrin inclusion complex loaded controlled release matrix tablets of famotidine were systematically optimized using experimental design. A central composite design was used for optimization of the two factors, concentrations of HPMCK4M and HPMCK15M, at three levels (low, medium and high). Dissolution was used as a response parameter for the prepared tablet formulations, which include Q18h (percent drug release in 18 h time period) and T90% (time required for 90% drug release). On evaluating all pre-compression parameters, it was found that the granules of formulations containing drug-β- cyclodextrin complex showed better flow ability rather than the formulations containing pure drug. Drug content for all formulations were found in the range of 95.72 to 98.78 with low standard deviation, which indicates the content uniformity of the prepared formulation batches. Formulation F7 containing 62% HPMCK15M and 38% HPMCK4M showed 88.02% release within 12 hours of dissolution study and formulation F13 containing complexed drug with same polymer blend ratio showed 98.92% release that was controlled up to 12 hours. All the formulations were stored at 40±5 ºC, 70±2%RH and subjected to stability studies upto 90 days. It showed that all the formulations are physically and chemically stable.

Keywords: Famotidine, histamine receptor blocker, bioavailability, controlled release matrix tablet, cyclodextrin.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2021 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR: NOVEMBER ISSUE PUBLISHED

    NOVEMBER Issue has been successfully launched on 1 November 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )